uniQure NV Gets a Buy Rating from Chardan Capital

Chardan Capital analyst Gbola Amusa maintained a Buy rating on uniQure NV (NASDAQ: QURE) today and set a price target of $50. The company’s shares opened today at $34.81.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 24.8% and a 53.2% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for uniQure NV with a $50 average price target, which is a 43.6% upside from current levels. In a report released yesterday, B.Riley FBR also initiated coverage with a Buy rating on the stock with a $50 price target.

.

See today’s analyst top recommended stocks >>

Based on uniQure NV’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $18.79 million. In comparison, last year the company had a GAAP net loss of $20.27 million.

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.